KRMD Earnings

KRMD reported its FY2025Q4 earnings on 2026-03-12, showcasing a revenue of against an estimate of 10.89M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.02 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following KRMD's FY2025Q4 earnings announcement on 2026-03-12, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, KRMD's stock price tends to shift by an average of 4.33% in the 10 days leading up to earnings and 8.4% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate KRMD's annual revenue to reach 10.46M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between KRMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KRMD's stock price typically moves by 4.33% in the 10 days before its earnings and 8.4% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.01 and revenue of 10.46M.

The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.